Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Cirillo A, Marinelli D, Romeo U, Messineo D, De Felice F, De Vincentiis M, Valentini V, Mezi S, Valentini F, Vivona L, Chiavassa A, Cerbelli B, Santini D, Bossi P, Polimeni A, Marchetti P, Botticelli A.
Cirillo A, et al. Among authors: valentini f.
BMC Cancer. 2024 Apr 17;24(1):487. doi: 10.1186/s12885-024-12249-y.
BMC Cancer. 2024.
PMID: 38632499
Free PMC article.
No abstract available.